Is ERα a Tamoxifen Predictive Factor in ERα Negative Breast Cancer in Premenopausal Women?

被引：0
|
作者：
Kallstrom, A-C
Ferno, M.
Jonsson, P. E.
Landberg, G.
Nordenskjold, B.
Stal, O.
机构：
[1] Helsingborgs Lasarett, Helsingborg, Sweden
[2] Linkoping Univ, S-58183 Linkoping, Sweden
[3] Lund Univ, S-22100 Lund, Sweden
[4] Lund Univ, Malmo, Sweden
[5] Lund Univ, Malmo Univ Hosp, Malmo, Sweden
[6] Univ Manchester, Manchester M13 9PL, Lancs, England
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-PD05-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD05-06
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Modulation of transforming growth factor beta expression and induction of apoptosis by tamoxifen in ER positive and ER negative breast cancer cells
    Benson, JR
    Baum, M
    BRITISH JOURNAL OF CANCER, 1996, 74 (06) : 993 - 994
  • [2] Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ
    Mishra, Ameet K.
    Abrahamsson, Annelie
    Dabrosin, Charlotta
    ONCOTARGET, 2016, 7 (35) : 56876 - 56888
  • [3] Tamoxifen for treatment of premenopausal women with breast cancer
    Lam, RY
    Chlebowski, RT
    CANCER INVESTIGATION, 2000, 18 (07) : 681 - 684
  • [4] Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPER
    Girgert, Rainer
    Emons, Guenter
    Gruendker, Carsten
    FRONTIERS IN ENDOCRINOLOGY, 2019, 9
  • [5] Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor -: Positive premenopausal breast cancer
    Giltnane, Jennifer M.
    Ryden, Lisa
    Cregger, Melissa
    Bendahl, Par-Ola
    Jirstrom, Karin
    Rimm, David L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (21) : 3007 - 3014
  • [6] CYP2D6 polymorphisms are not associated with tamoxifen outcome in premenopausal women with ER positive breast cancer of the POSH cohort
    Saladores, Pilar H.
    Schroth, Werner
    Eccles, Diana
    Tapper, William
    Gerty, Sue
    Brauch, Hiltrud B.
    CANCER RESEARCH, 2012, 72
  • [7] MCM2 is involved in subtyping and tamoxifen resistance of ERα-positive breast cancer by acting as the downstream factor of ERα
    Liu, Sainan
    Liang, Zhuoshuai
    Wang, Yujian
    Ren, Yaxuan
    Gu, Yulu
    Qiao, Yichun
    He, Huan
    Li, Yong
    Cheng, Yi
    Liu, Yawen
    BIOTECHNOLOGY JOURNAL, 2024, 19 (02)
  • [8] AIB1 is a predictive factor for tamoxifen response in premenopausal women
    Alkner, S.
    Bendahl, P. -O.
    Grabau, D.
    Lovgren, K.
    Stal, O.
    Ryden, L.
    Ferno, M.
    ANNALS OF ONCOLOGY, 2010, 21 (02) : 238 - 244
  • [9] Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer
    Marco Colleoni
    Elisabetta Munzone
    Drugs, 2015, 75 : 1311 - 1321
  • [10] Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer
    Colleoni, Marco
    Munzone, Elisabetta
    DRUGS, 2015, 75 (12) : 1311 - 1321
12345